טוען...
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science (PLoS)
2018-01-01
|
| סדרה: | PLoS ONE |
| גישה מקוונת: | http://europepmc.org/articles/PMC5976165?pdf=render |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|